For definition of Groups, see Preamble Evaluation.
Supplement 7:: (1987) (p. 391)
Chem. Abstr. Name: 2-S-trans)-7-Chloro-2',4,6-trimethoxy-6'-methylspiro[benzofuran-2(3H),1'-(2)-cyclohexene]-3,4'-dione
A. Evidence for carcinogenicity to animals (sufficient)
Griseofulvin induced liver tumours following its oral administration to adult mice [ref: 1-3] or its subcutaneous administration to infant male mice [ref: 1]. When given orally to rats and hamsters, it produced a significant increase in the incidence of thyroid tumours in rats but had no carcinogenic effect in hamsters [ref: 2].
Griseofulvin is possibly carcinogenic to humans (Group 2B).
For definition of the italicized terms, see Preamble Evaluation.
Subsequent evaluation: Vol. 79 (2001)
Also see previous evaluation: Vol. 10 (1976)
1. IARC Monographs, 10, 153-161, 1976
2. Rustia, M. & Shubik, P. (1978) Thyroid tumours in rats and hepatomas in mice after griseofulvin treatment. Br. J. Cancer, 38, 237-249
3. Chlumská, A.A. & Janousek, V. (1981) Hepatomas after long-term administration of griseofulvin (Czech.). Cesk. Patol., 17, 83-87
See Also: Toxicological Abbreviations Griseofulvin (IARC Summary & Evaluation, Supplement7, 1987) Griseofulvin (IARC Summary & Evaluation, Volume 79, 2001)